Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

18.77

+0.68

(+3.76%)

At close: 04:00PM EDT

18.95

+0.18

(+0.96%)

After hours:

07:51PM EDT

Advertisement

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Neutralpattern detected

All

Simply Wall St.
Is Editas Medicine (NASDAQ:EDIT) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Zacks
Editas' (EDIT) Loss Narrows in Q2, Revenues Trump Estimates
Editas (EDIT) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates. Focus remains on the lead candidate, EDIT-101.
Motley Fool
Why Editas Medicine Was Winning on Wednesday
Shares of Editas Medicine (NASDAQ: EDIT) were rocketing more than 13% higher in late-afternoon trading on Wednesday, and it was little wonder. The company scored twin beats in its latest set of quarterly results, with one line item in particular being a standout. The genome editing company's revenue was $6.3 million.

Advertisement